Pneumococcal disease, caused by a type of bacterium called Streptococcus pneumoniae, is one of the largest vaccine-preventable causes of death in children and older adults worldwide. While pneumococcal vaccines are given to children regularly, adults — particularly seniors — are still at risk of serious illness from the disease due to low rates of vaccination.
Researchers are studying an investigational vaccine that may provide protection against pneumococcal disease in adults. This study will test the effectiveness and safety of an investigational pneumococcal vaccination given with an approved flu vaccine.
- Must be age 50 or older
- Must NOT have had pneumococcal disease within the past 3 years
- Must NOT have received a pneumococcal vaccine within the past 12 months, nor a flu vaccine within the past 6 months
- Will receive an approved flu vaccine and an investigational pneumococcal vaccine over the course of 2 or 3 study visits
- Will receive compensation for study-related time; reasonable travel cost will be reimbursed
- Do not need insurance to join this study
For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.
You can also talk to a Meridian enrollment specialist about this study by calling (912) 623-2240.
Submit your information
Meridian Clinical Research
415 Hooper Road
Endwell, NY 13760
Founded in 1999 in Omaha, NE, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services. Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For more than 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.